About Us
Company Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Approach
The Opportunity in China
The Everest Advantage
Partners
Pipeline
Media
Investors
News
Search
19
2022/09
Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth
26
2022/08
Everest Medicines Announces the Departure of CEO, Kerry Blanchard
24
2022/08
Everest Medicines Announces Interim Results for First Half of 2022
16
2022/08
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy
®
in Asia Territories
11
2022/08
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan
18
2022/07
Everest Medicines Announces European Commission Grants Approval of Kinpeygo
®
for Adults with Primary IgA Nephropathy to our Partner Calliditas Therapeutics
10
2022/06
Everest Medicines Announces Approval of Trodelvy
®
in China for Second-Line Metastatic Triple-Negative Breast Cancer
04
2022/06
Everest Medicines’ Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy
®
in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
24
2022/05
Everest Medicines’ Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis
07
2022/04
Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business
06
2022/04
Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
31
2022/03
Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
<<
<
1
2
3
4
5
6
7
8
9
10
>
>>
Copyright Everest Medicines 2020 云顶药业(苏州)有限公司
苏ICP备20038571号
|
Terms of Use
|
Privacy Policy
|
Disclaimers
沪公网安备 31010602006477号
a>